Perrigo Company PLC (PRGO) reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) reached $0.80, surpassing Wall Street's consensus estimate of $0.77 by $0.03. However, revenue for the quarter totaled $1.0 billion, falling short of the anticipated $1.1 billion.
The results reflect the company's performance in the competitive pharmaceuticals industry, where it operates as a provider of consumer self-care products and over-the-counter health solutions. Perrigo's segments include Consumer Self-Care Americas and Consumer Self-Care International, with a focus on developing and marketing products that enhance individual well-being.
Perrigo will host its earnings conference call to discuss these results further and provide additional insights into its business performance. Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's results and future outlook.
As of November 8, 2025, Perrigo holds a market capitalization of $2,000.37 million. The company has an EPS (TTM) of -0.58 and a striking dividend yield of 777.0%. Looking ahead, upcoming earnings are scheduled for February 22, 2026, with an EPS estimate of 0.9183 and revenue expectations of $1.1 billion.